NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ MỤN TRỨNG CÁ VÙNG NGỰC LƯNG BẰNG ÁNH SÁNG LED, FOB 10 LOTION, E-PSORA CỦA BỆNH NHÂN TẠI VIỆN NGHIÊN CỨU DA THẨM MỸ QUỐC TẾ FOB® NĂM 2023-2025

Abstract

Background: The clinical characteristics of truncal and facial acne are considered distinct, with truncal acne potentially leading to hypertrophic scarring. Currently, guidelines for managing truncal acne are limited and primarily adapted from facial acne management protocols. A new therapy that is fast, safe, effective and has no side effects such as LED light combined with FOB 10 Lotion and E-PSORA that affects the pathogenesis of acne is considered an alternative treatment approach for acne. Objectives: To evaluate the clinical characteristics and treatment results of truncal acne. Materials and methods: This interventional study without a control group was conducted on 82 patients diagnosed with truncal acne at FOB International Cosmetic Dermatology Institute in 1/2023-1/2025. Results: The most affected age group was 18-24 years (48.8%). The most common symptom was pruritus (61%), and the most frequently involved site was the back (30,5%). The predominant lesion types were comedones (90.2%), papules (72%), and hypertrophic scars (32.9%). Moderate acne severity based on the Physician’s Global Assessment (PGA) scale was the most prevalent (62.2%). Compared to baseline (T0), the number of inflammatory and noninflammatory lesions decreased by 65.3% and 74.4%, respectively, at week 3 (T3) (p < 0.001). After three weeks (T3), 71.9% of patients achieved a PGA score of 0 or 1, with 57.3% demonstrating a good response and 33% showing a moderate response. The most common adverse effect was dry skin (3.7%). Conclusion: Treatment of truncal acne with LED therapy, FOB 10 Lotion, and EPSORA significantly improved disease severity, particularly in inflammatory and non-inflammatory lesions.